Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive technology, focusing on efficient use of NGS in liquid biopsies for cancer diagnostics.
This year’s edition saw a rise in overall attendees, with harmonization and innovation driving increased industry dynamism
Frontage Holdings Corporation announced 11736655 CANADA LTD., an indirectly wholly-owned subsidiary of the Group through Frontage Laboratories, Inc., entered into a share purchase agreement with J&J Corporate Services, Inc., an independent third party.
Summit Therapeutics plc reports its financial results and provides an update on its operational progress for the third quarter and nine months ended 31 October 2019.
IBA, the world’s leading provider of solutions for the diagnosis and treatment of cancer, announces that it has sold RadioMed Corporation, IBA’s VISICOIL™ fiducial markers business, to IZI Medical Products LLC, a leading interventional medical device company in a deal that is worth between USD 14 and 16 million to IBA.
Immuneering Corporation has announced the completion of a $17 million Series A financing.
Latest funding caps year of groundbreaking milestones for transformative vascular access company; new capital will be used to meet rapidly growing hospital and patient demand
The companies had to undergo a number of delays as regulatory agencies from across the globe looked closely at the deal to see if there was a potential the combined companies could create a monopoly in the market and stifle competition.
AELIS FARMA, a biotechnology company specialized in the treatment of brain disorders, announces the completion of a €11 million financing round from the Region Nouvelle Aquitaine, Inserm Transfert Initiative, Bpifrance and the ACI, NACO and Aelis Innovation regional funds.